Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GV-100 SAD/MAD, Food Effect, and DDI Study in Healthy Participants
NCT07788014Phase 1Recruiting
- Sponsor
- Gilva Therapeutics
- Start
- Jun 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in autosomal dominant polycystic kidney disease (ADPKD) comparing GV-100 with Placebo (2 arms). Primary endpoint: Adverse Events at 7 weeks. Started Jun 2026; status: recruiting.
02
Drugs
GV-100
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT07788014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07788014.